HOME > About Walvax > Product

Haemophilus Influenzae Type b Conjugate Vaccine

 Market Approval time
The product was on market officially in April 2, 2007
 Introduction
DESCRIPTION
Haemophilus Influenzae Type b Conjugate Vaccine is a colorless and clear solution prepared by covalently bounding Haemophilus influenzae type b capsular polysaccharide antigen to tetanus toxoid protein.

Each dose of 0.5ml contains:
Haemophilus influenzae type b capsular polysaccharide…....……10μg
Tetanus toxoid protein………………………………………...............20~34μg
Sodium Chloride ………………………………............................3.75~4.75mg

INDICATIONS
The vaccine is indicated for children 2 months to 5 years of age for the prevention of invasive infections caused by Haemophilus influenzae Type b, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis etc.

The vaccine is not to be used for the treatment of disease caused by othertypes of Haemophilus influenzae.

ADMINISTRATION AND DOSAGE
The vaccine is for intramuscular injection at the buttock or in the deltoid region.Each singe human dose is 0.5ml.

Infants at 2 months of age: Three injections (each dose is 0.5ml) shall be given at an interval of 1 or 2 months, and booster dose shall be given at 18 months of age.
Children at 6-12 months of age: Two injections (each dose is 0.5ml) shall be given at an interval of 1 or 2 months, and booster dose shall be given at 18 months of age.
Children at 1-5years of age: only one injection (0.5ml) is required.

PACKAGING
1 dose per vial accompanied with 1 vial of 0.5ml diluent.

SHELF LIFE
24 months.
 

免责声明: 本站资料及图片来源互联网文章,本网不承担任何由内容信息所引起的争议和法律责任。所有作品版权归原创作者所有,与本站立场无关,如用户分享不慎侵犯了您的权益,请联系我们告知,我们将做删除处理!